Physician profile
Caroline Eri Hong
NPI 1700352382
$3,157.22
in general payments reported to CMS, 2019-2025
25 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Occupational Health (Nurse Practitioner) provider received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,635 · 2024: $1,311 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,157.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.45 | 2023-2024 | |
| Celgene Corporation | $357.47 | 2023-2024 | Zeposia |
| Janssen Biotech, INC. | $327.95 | 2023-2024 | Stelara, Remicade, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $271.60 | 2023-2024 | Entyvio, Gattex |
| Pfizer INC. | $196.62 | 2023-2025 | |
| Gilead Sciences, INC. | $187.76 | 2023-2024 | |
| Lilly USA, LLC | $153.78 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $149.90 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.68 | 2023-2024 | Trulance, Xifaxan |
| Genzyme Corporation | $126.24 | 2023-2024 | |
| Qol Medical, LLC | $112.51 | 2023-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $77.61 | 2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $72.95 | 2023 | Rebyota |
| Aimmune Therapeutics, INC. | $62.68 | 2024 | |
| Ardelyx, INC. | $52.86 | 2024 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $45.67 | 2024 | Bylvay |
| Amgen INC. | $44.68 | 2023 | Avsola, Amjevita |
| Janssen Scientific Affairs, LLC | $43.64 | 2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $39.41 | 2024 | Voquezna |
| Albireo Pharma, INC. | $20.94 | 2023 | Bylvay |
| Ironwood Pharmaceuticals, INC | $19.75 | 2023 | Linzess |
| Evoke Pharma, INC. | $18.85 | 2024 | |
| Nestle Healthcare Nutrition INC. | $17.28 | 2023 | |
| Fresenius Kabi USA, LLC | $16.19 | 2023 | Idacio |
| Teva Pharmaceuticals USA, INC. | $15.75 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.